Haleon has no immediate plans for acquisitions or divestments - Reuters

Mar. 02, 2023 12:47 PM ETHaleon plc (HLN)GSKBy: Jonathan Block, SA News Editor

Haleon (NYSE:HLN), the consumer health company spun off in 2022 from GlaxoSmithKline (GSK), has no immediate plans to engage in any acquisitions or divestments, according to CEO Brian McNamara.
Though he wouldn't rule out such activity at some point in the future, "there's certainly nothing imminent that is out there that I would talk about today," he told Reuters.
McNamara told the news service he expects inflation to continue to rise in 2023. While he expects Haleon (HLN) to experience 4%-6% growth this year, that will come more from price increases than increased sales of products.
Read why Seeking Alpha contributor Yannick Frey considers Haleon (HLN) a buy.